| 1. |
- Carmeliet, Peter, et al.
(author)
-
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
- 2001
-
In: Nature Medicine. - : Springer Science and Business Media LLC. - 1546-170X .- 1078-8956. ; 7:5, s. 575-583
-
Journal article (peer-reviewed)abstract
- Vascular endothelial growth factor (VEGF) stimulates angiogenesis by activating VEGF receptor-2 (VEGFR-2). The role of its homolog, placental growth factor (PlGF), remains unknown. Both VEGF and PlGF bind to VEGF receptor-1 (VEGFR-1), but it is unknown whether VEGFR-1, which exists as a soluble or a membrane-bound type, is an inert decoy or a signaling receptor for PlGF during angiogenesis. Here, we report that embryonic angiogenesis in mice was not affected by deficiency of PlGF (Pgf-/-). VEGF-B, another ligand of VEGFR-1, did not rescue development in Pgf-/- mice. However, loss of PlGF impaired angiogenesis, plasma extravasation and collateral growth during ischemia, inflammation, wound healing and cancer. Transplantation of wild-type bone marrow rescued the impaired angiogenesis and collateral growth in Pgf-/- mice, indicating that PlGF might have contributed to vessel growth in the adult by mobilizing bone-marrow-derived cells. The synergism between PlGF and VEGF was specific, as PlGF deficiency impaired the response to VEGF, but not to bFGF or histamine. VEGFR-1 was activated by PlGF, given that anti-VEGFR-1 antibodies and a Src-kinase inhibitor blocked the endothelial response to PlGF or VEGF/PlGF. By upregulating PlGF and the signaling subtype of VEGFR-1, endothelial cells amplify their responsiveness to VEGF during the 'angiogenic switch' in many pathological disorders.
|
|
| 2. |
- Fonteneau, Jean Francois, et al.
(author)
-
Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells
- 2003
-
In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 102:13, s. 4448-4455
-
Journal article (peer-reviewed)abstract
- Major histocompatibility complex (MHC) class I presentation of exogenous antigens is the mechanism enabling professional antigen-presenting cells (APCs) to induce CD8+ T-cell responses against viruses and tumors that do not have access to the classical MHC class I pathway. We have characterized the uptake, processing, and MHC class I cross-presentation by human dendritic cells (DCs) of cell-associated antigens derived from physiologically relevant sources, namely, vaccinia virus-infected apoptotic and necrotic cells. We show that cross-presentation is a rapid process, detectable within 2 to 4 hours after uptake of dead cells, and that proteolysis by cathepsin D in an acidic endosomal compartment is essential for cross-presentation. The presentation is abolished when the phagocytic or macropinocytic functions of the cells are inhibited and is dependent on transporter associated with antigen processing, sensitive to brefeldin A, and requires functional proteasomes. Altogether, these data suggest that antigens derived from apoptotic and necrotic cells require access to the cytosol to intersect with the conventional MHC class I pathway for presentation of cytosolic proteins.
|
|
| 3. |
|
|
| 4. |
- Ollivaux, Céline, et al.
(author)
-
Enkephalinergic control of the secretory activity of neurons producing stereoisomers of crustacean hyperglycemic hormone in the eyestalk of the crayfish Orconectes limosus.
- 2002
-
In: Journal of Comparative Neurology. - 0021-9967 .- 1096-9861. ; 444:1, s. 1-9
-
Journal article (peer-reviewed)abstract
- A subgroup of neurons in the classical X organ sinus gland neuroendocrine system of the crayfish (Orconectes limosus) eyestalk produces two chiral forms of the crustacean hyperglycemic hormone (CHH) in two different types of neurons: CHH in 22 cells and D Phe(3) CHH in eight cells. Previous reports have demonstrated that release of CHH from the sinus gland is inhibited by enkephalins. Here, we have addressed the questions of 1) whether this inhibition affects one or both types of CHH neurons, 2) where the site of enkephalinergic control of CHH and/or D Phe(3) CHH is, and 3) whether the inhibitory effect is due to direct or indirect interactions of enkephalinergic neurons with CHH cells. In vitro incubations of neurosecretory complexes followed by immunoassays of CHH isoforms indicated that both methionine and leucine enkephalins inhibit release of the two CHH isoforms from crayfish eyestalks, by a receptor mediated process. Whole mount double or triple immunofluorescence labelings combined with confocal microscopy revealed enkephalin immunostaining in all neuropils of the eyestalk, except in the sinus gland. Virtual thin confocal sections showed many close appositions between terminals of enkephalinergic neurons and dendritic arborizations of specific CHH immunoreactive cells in the medulla terminalis neuropil. This provides the first evidence for direct inputs from enkephalinergic neurons into dendrites of both CHH cell types, which suggests that enkephalins inhibit release of both CHH isoforms via synaptic contacts.
|
|
| 5. |
- Speiser, Daniel E, et al.
(author)
-
Ex vivo analysis of human antigen-specific CD8+ T-cell responses : quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring.
- 2004
-
In: Journal of immunotherapy (1997). - 1524-9557 .- 1537-4513. ; 27:4, s. 298-308
-
Journal article (peer-reviewed)abstract
- The authors developed a standardized approach for immune monitoring of antigen-specific CD8+ T cells within peripheral blood lymphocytes (PBLs) that combines direct ex vivo analysis of Melan-A/MART-1 and influenza-specific CD8+ T cells with HLA-A2/peptide multimers and interferon-gamma ELISPOT assays. Here the authors assessed the quality of results obtained with 180 PBLs from healthy donors and melanoma patients. Reproducibility of the multimer assay was good (average of 15% variation). In the absence of in vivo antigen-specific T-cell responses, physiologic fluctuations of multimer-positive T cells was low, with variation coefficients of 20% for Melan-A and 28% for influenza-specific T cells. In contrast, patients with vaccination-induced T-cell responses had significantly increased T-cell frequencies clearly exceeding physiologic fluctuations. Comparable results were obtained with ELISPOT assays. In conclusion, this approach is well suited to assess T-cell responses as biologic endpoints in clinical vaccine studies.
|
|
| 6. |
|
|
| 7. |
- Zippelius, Alfred, et al.
(author)
-
Effector function of human tumor-specific CD8 T cells in melanoma lesions : a state of local functional tolerance.
- 2004
-
In: Cancer Research. - 0008-5472 .- 1538-7445. ; 64:8, s. 2865-73
-
Journal article (peer-reviewed)abstract
- Although tumor-specific CD8 T-cell responses often develop in cancer patients, they rarely result in tumor eradication. We aimed at studying directly the functional efficacy of tumor-specific CD8 T cells at the site of immune attack. Tumor lesions in lymphoid and nonlymphoid tissues (metastatic lymph nodes and soft tissue/visceral metastases, respectively) were collected from stage III/IV melanoma patients and investigated for the presence and function of CD8 T cells specific for the tumor differentiation antigen Melan-A/MART-1. Comparative analysis was conducted with peripheral blood T cells. We provide evidence that in vivo-priming selects, within the available naive Melan-A/MART-1-specific CD8 T-cell repertoire, cells with high T-cell receptor avidity that can efficiently kill melanoma cells in vitro. In vivo, primed Melan-A/MART-1-specific CD8 T cells accumulate at high frequency in both lymphoid and nonlymphoid tumor lesions. Unexpectedly, however, whereas primed Melan-A/MART-1-specific CD8 T cells that circulate in the blood display robust inflammatory and cytotoxic functions, those that reside in tumor lesions (particularly in metastatic lymph nodes) are functionally tolerant. We show that both the lymph node and the tumor environments blunt T-cell effector functions and offer a rationale for the failure of tumor-specific responses to effectively counter tumor progression.
|
|
